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E-mail address: mariko.taga@inserm.fr (M. Taga).The mammalian target of rapamycin complex 1 (mTORC1) pathway including p70S6K (the 70-kDa
p70 S6 kinase) and S6, controls protein synthesis, has anti-apoptotic functions and can phosphory-
late tau protein. mTORC1 is triggered by nutrients such as phosphatidic acid (PA). Previous experi-
mental studies have shown that oxidative stress may down-regulate this pathway leading to
neuronal death. Our results showed that in human neuroblastoma cells, PA exposure can reduce
H2O2-induced apoptosis and can increase tau protein phosphorylation on Ser214 via p70
S6K activa-
tion. These ﬁndings reveal that PA, via the mTOR kinase, can trigger tau phosphorylation on a site
known to reduce paired helical ﬁlament (PHF) formation.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
In mammalian cells, the rapamycin-sensitive complex mamma-
lian target of rapamycin complex 1 (mTORC1), includesmTOR, a ser-
ine-threonine kinase, raptor and G protein beta protein subunit-like
(GbL) and is involved in the regulation of transcription, translation,
autophagy in response to nutrients [1,2]. Two main targets of
mTORC1are p70 ribosomal S6 kinase (p70S6K), a serine threonine ki-
nase which in turn activates the 40S ribosomal protein S6 (rpS6)
[3,4] and the binding protein of eukaryotic translation initiation fac-
tor eIF4E (4E-BP1) [5].
The involvement of mTOR/p70S6K/rpS6 in survival signaling
pathway was previously described [6,7]. mTOR functions are im-
paired in response of stressful stimuli [8]. In cell cultures, Ab and
oxidative stress (OS) treatment decreased phosphorylated form of
p70S6K on serine 389 (p70S6K (Thr389)) [2,9–11] that is correlated
with neuronal death [12]. In patients with Alzheimer’s disease
(AD), it has been shown a decrease of p70S6K (Thr389) in the cortex
and blood lymphocytes of AD patients. These data suggest that
mTORC1/p70S6K could be involved in neuronal death. Furthermore,chemical Societies. Published by E
essources et de Recherche,
-Louis, Université Paris VII, 2
958495.a recent study has shown that p70S6K is involved in protein tau
phosphorylation on serine 214 which strongly inhibits tau aggrega-
tion and paired helical ﬁlaments (PHF) formation [13,14].
The mTORC1/p70S6K/rpS6 pathway can be regulated by phos-
pholipase D (PLD) and phosphatidic acid (PA), [15–17]. PA, a
phospholipid used as a food supplement, binds directly to the
FRB domain of mTOR, and competes with rapamycin binding.
The direct binding of PA on FRB domain activates mTORC1, leading
to the phosphorylation of p70S6K/rpS6 and 4E-BP1 [15,18].
The aim of this study was to know if mTORC1 pathway stimu-
lated by PA can modulate the pro-apoptotic effects induced by OS
and can control tau phosphorylation on serine 214. In SH-SY5Y cell
cultures, our results show that stimulation ofmTORC1 by PA can re-
duce the toxicity of OS and induces tau phosphorylation at a site
that can prevent PHF formation.
2. Materials and methods
SH-SY5Y human neuroblastoma cell lines were obtained from
the American Type Culture Collection (ATCC). Cells were treated
with 0.5 mM of H2O2 for 2 h and when necessary were pre-treated
with 200 lM of PA for 30 min before H2O2 treatment. Two hundred
micromolar is the optimal concentration of PA to observe the phos-
phorylation of p70S6K. According to Frondorf et al. [19], treatment
with PA was repeated every 30 min because of its short half-lifelsevier B.V. All rights reserved.
Fig. 1. Immunoblot analysis of the effect of PA on mTORC1 activity in SH-SY5Y. (A)
Western blot of SH-SY5Y proteins with speciﬁcal antibody for p70S6K, p70S6K
(Thr389), rpS6 and rpS6 (Ser240/244 and Ser235/236). (B, C) H2O2 treatment
decreased the phosphorylation of p70S6K (94%) and the phosphorylation of rpS6 at
Ser235/236 and at Ser240/244 (73%) while PA lead to an increase (52% and 487%,
respectively) compared to controls. With concomitants PA and H2O2 treatments, PA
attenuated the effect of H2O2 (7% and 10%, respectively) (⁄P < 0.05; ⁄⁄⁄P < 0.001).
Fig. 2. Immunoblot analysis of the effect of rapamycin on PA effect in SH-SY5Y. (A)
Western blotting studies of the rapamycin treatment in SH-SY5Y cells. (B, C)
Histogram representation of the effect of rapamycin treatment in SH-SY5Y cells
showing a partial attenuation of PA effect leading to a decrease of p70S6K (Thr389)
level (45%) (B), and of rpS6 (Ser235/236) and of rpS6 (Ser240/244) (91%) (C)
(⁄P < 0.05; ⁄⁄⁄P < 0.001).
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pre-treated with 1, 2 or 5 lM of rapamycin, diluted in dimethyl
sulfoxide (DMSO), 1 h before PA treatment. To evaluate apoptosis,we used anti-poly ADP ribose polymerase (PARP), a nuclear poly
polymerase cleaved by caspase 3.
Bound proteins on Western blot membranes were visualized
with the Odyssey Imaging System (Li-COR biosciences) and then
quantiﬁed with Multigauge software (Fujiﬁlm). All quantiﬁcations
were normalized ona-tubulin, or b-actin levels. Results were evalu-
ated with phosphorylated form to full length form ratio of the pro-
tein. Results were obtained from at least three independent
experiments and were considered signiﬁcant when P < 0.05 using
Analysis of Variance Test (ANOVA) with GraphPad Prism 5
(Graphpad Software Inc., La Jolla, CA 92037, USA).
Fig. 3. Western blotting studies of PA exposure and oxidative stress in SH-SY5Y cells. (A, B) The cleaved PARP level progressively decreased by 36% in cells treated by 200 lM
of PA and to 60% in cells treated by 500 lM (⁄P < 0.05; ⁄⁄⁄P < 0.001). (C, D) Immunoblot analysis showed that H2O2 exposure increased the cleaved PARP more than 50% while
PA treatment decreased H2O2 effect on apoptosis by 64% (⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001).
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3.1. Stimulation of mTORC1 activity by PA during OS
To explore the effect of PA on mTORC1 phosphorylation, cells
were pre-treated by PA and/or exposed to H2O2 for 2 h. The levels
of p70S6K (Thr389) and rpS6 were used as the reﬂect of mTORC1
activation. The results showed that PA exposure lead to a signiﬁ-
cant increase of p70S6K (Thr389) (P < 0.05) and of rpS6 (Ser235/
236 and 240/244). At the opposite, H2O2 exposure alone induced
a signiﬁcant decrease of p70S6K (Thr389) (P < 0.001) and of rpS6
(Ser235/236 and 240/244) (Fig. 1A). PA and H2O2 co-treatments
led to a signiﬁcant increase of p70S6K (Thr389) compared to H2O2
treatment alone (P < 0.05). These results suggest that PA induced
the reduction of OS effects on p70S6K (Fig. 1B) and rpS6 (Fig. 1C)
phosphorylations.
3.2. PA stimulates p70S6K phosphorylation via mTORC1
To determine if PA acts directly on mTORC1, we inhibited its
activation with rapamycin. Fig. 2 showed a clear reduction of
p70S6K activity reﬂected by a signiﬁcative reduction of rpS6 phos-
phorylation (Ser235/236 and 240/244) in cells treated by rapamy-
cin alone. Results also conﬁrmed an increase of mTORC1 activity in
the presence of PA (line 4) while H2O2 decrease its activity. In cells
pre-treated with rapamycin prior to PA treatment (line 6), the
analysis displayed a signiﬁcant decrease (P < 0.05) of rpS6 phos-
phorylation compared to cells treated by PA alone (Fig. 2C). These
results demonstrated that rapamycin attenuates the PA effect on
mTORC1 activation leading to a decreased activation of rpS6
(Ser235/236 and Ser240/244). This ﬁnding suggests that PA can
trigger the phosphorylation of rpS6 via mTORC1 activation.3.3. PA decreases apoptosis in SH-SY5Y cells
To study the effect of PA on spontaneous apoptosis, cells were
treated for 1 h by different concentrations of PA (Fig. 3A). The results
showeda signiﬁcant increase of the non-cleaved formof PARP (PARP
Total)while the cleaved formof PARP signiﬁcantlydecreases. The ef-
fects were dose-dependent. In this model, PA can protect cells
against spontaneous apoptosis. To explore the effect of PA on apop-
tosis induced by OS, cells were pre-treated or not by PA for 30 min
and then, with H2O2 for 2 h. The pro-apoptotic effect of H2O2 was
conﬁrmed by a signiﬁcant increase of PARP cleavage compared to
controls (Fig. 3C). The anti-apoptotic effect of PA was observed by
a signiﬁcant decrease of the PARP cleavage compared to controls
(Fig. 3D). A signiﬁcant decrease of the PARP cleavagewas also noted
in cells treated by PA and H2O2 compared to cells treated by H2O2
alone and to control cells. These results suggest that 200 lM of PA
can induce an anti-apoptotic effect on SH-SY5Y cells. The PA
pre-treatment decreases the apoptosis induced by OS in cell
cultures.
3.4. PA increases tau phosphorylation on Ser214 via mTOR activation
Fig. 4A and C shows that cells treated by PA alone (line 4)
revealed a signiﬁcant increase of Tau (Ser214), whereas treatments
with rapamycin (line 3) or H2O2 (line 2) lead to a decrease of Tau
(Ser214) levels. In cells treated by PA and H2O2, an increase of Tau
(Ser214) was detected compared to cells exposed to rapamycin or
H2O2 alone. The treatment by PA attenuates the effect of H2O2 on
the serine 214 tau phosphorylation in this model (Fig. 4C). Further-
more, we observed that treatment combining PA and rapamycin
leads to a mild decrease of Tau (Ser214) compared to cells treated
by PA alone. Our ﬁndings demonstrate that PA strongly controls
Fig. 4. Effect of PA on Tau (Ser214) phosphorylation. (A, B) Western blotting studies of phosphorylation of Tau (Ser214) with concomitants PA and rapamycin treatments. (C)
Quantiﬁcation of immunoblot showed that PA treatment increased Tau (Ser214) level by 281%, whereas H2O2 and rapamycin decreased it, respectively, by 27% and 47%. Cells
treated with 2 and 5 lM of rapamycin before PA treatment showed a decrease of Tau (Ser214), respectively, by 36% and 45% compared to PA treatment alone (⁄P < 0.05;
⁄⁄P < 0.01).
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action, we exposed PA pre-treated cells to 2 lM or 5 lM rapamycin
(Fig. 4B). The results showed a signiﬁcant decrease of Tau (Ser214)
in cells treated by PA and 2 lM or 5 lM of rapamycin compared
to treatment by PA alone. These ﬁndings conﬁrm the involvement
of the mTOR/p70S6K pathway on tau phosphorylation on Ser214 in-
duced by PA (Fig. 4C).
The summary of the mTOR pathway modulated by PA is
depicted in Fig. 5.
4. Discussion
Our data showed that the activation of mTORC1 by PA could
attenuate the OS effect in neuroblastoma cell line and increase
Tau (Ser214) level.
Our results showed a signiﬁcant increase of the p70S6K (Thr389)
of the rpS6 (Ser235/236 and Ser240/244) in neuroblastoma cells
treated by PA and were consistent with previous ﬁndingsperformed in other cell models [18]. In addition, we demonstrated
that the effect of OS in neuroblastoma cells on p70S6K phosphory-
lation was reversed by pre-exposure to PA. It was shown in a pre-
vious study that OS induced the dephosphorylation of p70S6K by
inhibiting Akt and phosphoinositide-dependent kinase-1 (PDK1)
and by activating of the AMP-activated protein kinase (AMPK)
[20]. In our results, the pre-treatment by PA avoid a decrease of
the p70S6K (Thr389) and of the rpS6 (Ser235/236 and Ser240/
244) levels, suggesting a persistence of mTORC1 activity in cells
exposed to OS.
According to an earlier work [18], PA binds directly to the
FKBP12-rapamycin binding (FRB) domain of mTOR, ﬁxation
domain of rapamycin [15]. To determine whether PA acts directly
on mTORC1, we treated SH-SY5Y cells with rapamycin to produce
a competition between PA and rapamycin. With concomitant treat-
ment (rapamycin + PA), results show that rapamycin attenuates the
rpS6 (Ser235/236 and Ser240/244) level close to the control level
(Fig. 2). This data suggests that PA acts directly on mTORC1 to in-
Fig. 5. Schematic diagram of the potential signaling pathways linked to PA: inhibition of apoptosis and induction of tau phosphorylation.
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shown that PA might act on mTORC1 by the extracellular signal-
regulated kinase (ERK) signaling pathway. Indeed, it seems that
exogenous PA is hydrolyzed in lysophosphatidic acid (LPA) by
phospholipid A (PLA), which binds to endothelial cell differentia-
tion gene 2 (EDG-2 receptor), resulting in activation of the PLD
and ERK signaling pathways [21]. Further study will be needed to
explore this pathway in the contribution to p70S6K phosphorylation.
We consequently explored the effect of PA on spontaneous
apoptosis and OS induced apoptosis. The results showed that
H2O2 increased cell apoptosis levels and that PA decreases apopto-
sis in presence or not of H2O2. These results conﬁrm the effect of
H2O2 on apoptosis [22] and show that mTORC1 activation leads to
apoptosis reduction. Actually, two opposite hypothesis exist to ex-
plain these ﬁndings. It was observed that mTOR activation was
implicated in neuronal death and could be pro and anti-apoptotic
[23]. On the one hand, mTORC1 inhibition by rapamycin leads to
a decrease of apoptosis and may induce a prevention of neurode-
generation [24]. On the other hand, studies revealed the anti-apop-
totic function and implication of mTORC1 in cell survival [7,25].
Phosphorylated p70S6K can bind to mitochondrial membranes and
can phosphorylate the pro-apoptotic protein Bad leading to its inac-
tivation [7,23]. In addition, a recent data has demonstrated that
DHEA-treatment (neurosteroid dehydroepiandrosterone) leads to
reduced death of newborn neurons and protects dendritic growth
and survival of newborn neurons via mTOR [26]. These studies rein-
force the hypothesis of anti-apoptotic functions of mTOR and its
involvement in cell survival.
The hyperphosphorylation of tau is a major neuropathological
phenomenon deﬁning PHF and tangles in AD [27]. Our results
showed that the inhibition of mTORC1 activity by rapamycin and
by H2O2 treatment lead to a decrease of phosphorylated Tau level
(Ser214). A earlier study revealed that the activation of p70S6K
leads to Tau (Ser214) and Tau (Ser262) phosphorylation and to
increase tau synthesis [13]. Another data has described that phos-
phorylation of Tau at Ser214 and Ser262 mainly produced by
p70S6K strongly reduces tau afﬁnity for microtubules, and inhibits
tau assembly into PHF [14]. Whether the action of p70S6K on tau
phosphorylation might be beneﬁcial remains to be further studied.In our results, a high concentration of rapamycin is necessary to
block or to decrease the effect of PA on tau phosphorylation. To
explain these results, we can suggest that other undeﬁned kinases,
activated by PA, could be implicated in Tau (Ser214) phosphoryla-
tion as well.
In conclusion these results show that PA in activating mTORC1,
has strong neuroprotective properties in vitro and can control tau
phosphorylation via p70S6K. Further studies will be necessary to
determine in vivo the potential properties of PA in the modulation
of neurodegeneration and tau phosphorylation.
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